Biosergen AB reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was SEK 0.292 million compared to SEK 0.493 million a year ago. Net loss was SEK 7.51 million compared to SEK 14.5 million a year ago. Basic loss per share from continuing operations was SEK 0.15 compared to SEK 0.51 a year ago. Diluted loss per share from continuing operations was SEK 0.15 compared to SEK 0.51 a year ago.
For the nine months, revenue was SEK 8.06 million compared to SEK 3.22 million a year ago. Net loss was SEK 20.57 million compared to SEK 27.47 million a year ago. Basic loss per share from continuing operations was SEK 0.48 compared to SEK 0.97 a year ago. Diluted loss per share from continuing operations was SEK 0.48 compared to SEK 0.97 a year ago.